Taysha Gene Therapies, Inc. Common Stock
TSHAStock
$5.97+115.91%52W
Market Cap$2.01B
P/E—
Div yield—
Beta1.25
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-0.31%
Price vs S&P 500 (4W)-4.13%
VGM Score49.73
Market Capitalization$2.01B
Earnings Surprise History
Q1 26-0.12est. -0.10
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.26
4.26
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TSHATaysha Gene Therapies, Inc. Common Stock | F | B | B | $5.97 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Taysha Gene Therapies develops AAV-based gene therapies for monogenic central nervous system diseases, targeting both rare and large patient populations. Its clinical-stage pipeline includes TSHA-102, a self-complementary AAV9 therapy delivered intrathecally for the treatment of Rett syndrome.